Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRE | P78334 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30886668 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1GABRPGABRD | |
| SCHEMBL104398 | 0.82 | SMN1; SMN2 (0.58) | ALDH1A1KMT2AMEN1KDM4EHPGD | |
| SCHEMBL3655613 | 0.80 | ALDH1A1 (0.42) | ALDH1A1KMT2AMEN1GABRPGABRD | |
| SCHEMBL25305134 | 0.80 | CSNK2A1 (0.41) | ALDH1A1KMT2AMEN1GABRPGABRD | |
| SCHEMBL30501179 | 0.80 | CSNK2A1 (0.41) | ALDH1A1KMT2AMEN1GABRPGABRD | |
| SCHEMBL18998283 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KMT2AMEN1GABRPGABRD | |
| SCHEMBL1713978 | 0.78 | ALDH1A1 (0.46) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3658112 | 0.75 | POLB (0.44) | ALDH1A1KMT2AMEN1GABRPGABRD | |
| SCHEMBL30517016 | 0.74 | NOTUM (0.43) | ALDH1A1KMT2AMEN1GABRPGABRD | |
| SCHEMBL20349185 | 0.74 | KMT2A (0.38) | ALDH1A1KMT2AMEN1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LTD (HK) | 2026-04-09 | — | — | US | disclosed |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2025-11-04 | — | — | US | disclosed |
| EP-4311577-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Ji Xing Pharmaceuticals Hong Kong Limited (HK) | 2024-01-31 | — | — | EP | disclosed |
| EP-3562487-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2023-11-29 | — | — | EP | disclosed |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2021-10-21 | — | — | US | disclosed |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| CN-110691598-A | Metalloenzyme inhibitor compounds | 赛列尼蒂治疗(百慕大)有限公司 | 2020-01-14 | — | — | CN | disclosed |
| EP-3562487-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Selenity Therapeutics (Bermuda), Ltd. (BM) | 2019-11-06 | — | — | EP | disclosed |
| US-20190008861-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2019-01-10 | — | — | US | disclosed |
| US-10085984-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-10-02 | — | — | US | disclosed |
| CN-102307853-A | Pyrrolidine derivatives as NK3 receptor antagonists | HOFFMANN LA ROCHE | 2012-01-04 | — | — | CN | disclosed |
| EP-2398768-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| US-8012998-B2 | Pyrrolidine aryl-ether as NK-3 receptor antagonists | Hoffmann—La Roche Inc. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2185540-B1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010094667-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
| CN-101778837-A | Pyrrolidine aryl-ether as nk3 receptor antagonists | HOFFMANN LA ROCHE | 2010-07-14 | — | — | CN | disclosed |
| EP-2185540-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009019163-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CYP11B2, CYP11B1, HSD11B2 | ALDH1A1 232/4885KMT2A 1496/4885MEN1 839/4885 |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | ALDH1A1 956/4885KMT2A 1397/4885MEN1 4851/4885 |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CPN1, TPP1, DPP4 | ALDH1A1 189/4885KMT2A 2003/4885MEN1 1831/4885 |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | ALDH1A1 457/4885KMT2A 2849/4885MEN1 720/4885 |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | ALDH1A1 457/4885KMT2A 2849/4885MEN1 720/4885 |
| US-20190008861-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | ALDH1A1 457/4885KMT2A 2849/4885MEN1 720/4885 |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | ALDH1A1 639/4885KMT2A 1000/4885MEN1 4841/4885 |
| US-10085984-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | ALDH1A1 457/4885KMT2A 2849/4885MEN1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.